Keros Therapeutics
KROS
99 hedge funds and large institutions have $944M invested in Keros Therapeutics in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 15 closing their positions.
131,300% more call options, than puts
Call options by funds: $6.57M | Put options by funds: $5K
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
73% more capital invested
Capital invested by funds: $545M → $944M (+$399M)
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
13% more funds holding
Funds holding: 88 → 99 (+11)
9.93% more ownership
Funds ownership: 59.12% → 69.05% (+9.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$18.9M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$17M |
| 3 |
Alkeon Capital Management
New York
|
+$11.2M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.48M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.44M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.74M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.57M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.33M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.27M |
KROS Hedge Fund Activity: Q4 2021 in Review
99 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2021, worth a combined $944M — up 73% from $545M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KROS positions and 15 closed out — a net gain of 11 holders — while 30 added to existing stakes and 24 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $18.9M. The largest seller was Millennium Management, cutting an estimated $6.44M.
- 99 institutional investors held Keros Therapeutics (KROS) as of Q4 2021, up from 88 in Q3 2021.
- Funds reported $944M of Keros Therapeutics stock for Q4 2021, up 73% quarter-over-quarter.
- 26 funds opened new Keros Therapeutics positions in Q4 2021 and 15 closed out, a net change of +11 holders.
- The largest Keros Therapeutics buyer in Q4 2021 was First Light Asset Management, an estimated $18.9M added.
- The largest Keros Therapeutics seller in Q4 2021 was Millennium Management, an estimated $6.44M sold.
Based on aggregated 13F filings for Q4 2021.